Skip to main content
. 2011 Feb 1;5:139–146. doi: 10.2147/OPTH.S15783

Figure 4.

Figure 4

Efficacy of the dexamethasone implant in improving BCVA stratified by the underlying cause of macular edema in patients who participated in the Phase II trial.

Notes: aP not determined; bP = 0.029 and cP = 0.007 compared with the observation group; duveitis or Irvine-Gass syndrome; en = 35 for the 0.7 mg dexamethasone implant; fn = 13 for the 0.7 mg dexamethasone implant.

Abbreviations: DEX, dexamethasone; BVCA, best corrected visual acuity.